ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 5 for:    Nestorone Testosterone

Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03452111
Recruitment Status : Not yet recruiting
First Posted : March 2, 2018
Last Update Posted : July 12, 2018
Sponsor:
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Population Council
Information provided by (Responsible Party):
Health Decisions

Brief Summary:
The long term objective is to develop a gel to be used as a male contraceptive.

Condition or disease Intervention/treatment Phase
Healthy Men Male Contraception Drug: Nestorone + Testosterone Combination Gel Phase 2

Detailed Description:

This is a prospective, phase IIb, open label, single arm, multicenter study. The study protocol consists of a screening phase lasting 4 to 8 weeks, a suppression phase estimated up to 20 weeks, a 52-week maintenance/efficacy phase, and a 24-week (estimated) recovery phase.

The study will involve approximately 420 couples recruited throughout the CCTN that meet eligibility criteria. The nine sites propose to enroll up to 420 couples (about 30 to 60 couples per site) with a goal of obtaining 200 couples completing the contraceptive efficacy phase of the study. The study has four phases (screening phase, suppression phase, efficacy phase and recovery phase) with monthly visits to provide the male participants with the NES-8/T-62 gel, to encourage adherence, to monitor for possible side effects, and to quantify semen parameters. The female will be contacted monthly and come in for a visit every three months.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 420 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Clinical Evaluation of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception
Estimated Study Start Date : August 2018
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : September 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Birth Control

Arm Intervention/treatment
Experimental: Nestorone (NES) + testosterone (T) combined gel
A combination Gel with Nestorone® (NES) and Testosterone (T) applied transdermally. The amount of gel to be applied daily will be approximately 5 mL in volume (2.5 mL to each shoulder and upper arm per day). This daily gel volume will contain approximately 62 mg of T that will deliver 6 mg T to the body per day and will also contain 8 mg of NES that will deliver about 0.8 mg NES to the body per day (NES 8 mg/day + T 62 mg/day (NES-8/T-62) gel).
Drug: Nestorone + Testosterone Combination Gel
The combined gel is a transdermal treatment that will be applied daily for 52 weeks to a male subject's arms and shoulders. The formulation will be a hydro alcoholic gel containing about 1.43% T (14.3 mg T/g gel). About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume. The gel application volume will contain 62 mg of T that will deliver approximately 6 mg T to the body per day. This gel volume will also contain 8 mg of NES that will deliver about 0.8 mg of NES to the body per day (NES 8 mg/d + T 62 mg/d (NES8/T62) gel).
Other Names:
  • NES/T gel
  • NES-8/T-62




Primary Outcome Measures :
  1. Contraceptive efficacy provided by the daily application of NES/T gel for 52 weeks during the efficacy phase of the study determined using Kaplan-Meier methods to estimate the 12 month cumulative pregnancy probability in the typical use population. [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Suppression of spermatogenesis induced by daily use of the NES/T gel as assessed by semen analyses using number of subjects with sperm concentration <1 million (M)/mL during the suppression phase of the study. [ Time Frame: 20 weeks ]
  2. Maintenance of suppression of spermatogensis induced by daily use of the NE/T gel as assessed by semen analyses using number of subjects with sperm concentration <1 million (M)/mL during the 52 week efficacy phase of the study. [ Time Frame: 52 weeks ]
  3. Changes from baseline in Follicle Stimulating Hormone (FSH) with daily use of the NES/T gel. [ Time Frame: 24 months ]
  4. Changes from baseline in Luteinizing Hormone (LH) with daily use of the NES/T gel. [ Time Frame: 24 months ]
  5. Changes from baseline in Sex Hormone Binding Globulin (SHBG) with daily use of the NES/T gel. [ Time Frame: 24 months ]
  6. Changes from baseline in Testosterone with daily use of the NES/T gel. [ Time Frame: 24 months ]
  7. Changes from baseline in Nestorone with daily use of the NES/T gel. [ Time Frame: 24 months ]
  8. Incidence of treatment emergent adverse events with daily use of the NES/T gel. [ Time Frame: 24 months ]
  9. Changes from baseline in sodium with daily use of the NES/T gel. [ Time Frame: 24 months ]
  10. Changes from baseline in potassium with daily use of the NES/T gel. [ Time Frame: 24 months ]
  11. Changes from baseline in chloride with daily use of the NES/T gel. [ Time Frame: 24 months ]
  12. Changes from baseline in bicarbonate with daily use of the NES/T gel. [ Time Frame: 24 months ]
  13. Changes from baseline in fasting glucose with daily use of the NES/T gel. [ Time Frame: 24 months ]
  14. Changes from baseline in blood urea nitrogen with daily use of the NES/T gel. [ Time Frame: 24 months ]
  15. Changes from baseline in creatinine with daily use of the NES/T gel. [ Time Frame: 24 months ]
  16. Changes from baseline in calcium with daily use of the NES/T gel. [ Time Frame: 24 months ]
  17. Changes from baseline in total bilirubin with daily use of the NES/T gel. [ Time Frame: 24 months ]
  18. Changes from baseline in alkaline phosphatase with daily use of the NES/T gel. [ Time Frame: 24 months ]
  19. Changes from baseline in alanine aminotransferase with daily use of the NES/T gel. [ Time Frame: 24 months ]
  20. Changes from baseline in aspartate transaminase with daily use of the NES/T gel. [ Time Frame: 24 months ]
  21. Changes from baseline in albumin with daily use of the NES/T gel. [ Time Frame: 24 months ]
  22. Changes from baseline in mood with daily use of the NES/T gel using the Patient Health Questionnaire-9. [ Time Frame: 24 months ]
  23. Changes from baseline in sexual function with daily use of the NES/T gel using the psychosexual daily questionnaire. [ Time Frame: 24 months ]
  24. Changes from baseline in prostate function with daily use of NES/T gel using the International Prostate Symptom Score. [ Time Frame: 24 months ]
  25. Acceptability of NES/T gel as a contraceptive among male and female participants using the acceptability questionnaires. [ Time Frame: 24 months ]
  26. Length of time to recovery of spermatogenesis after daily use of NES/T gel as assessed by sperm concentration > 15 million (M)/mL during the recovery phase. [ Time Frame: 24 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Male participant - Inclusion Criteria

Men who meet all the following criteria will be eligible for enrollment in the trial:

  1. Good health as confirmed by medical history, physical examination, and clinical laboratory tests of blood and urine at the time of screening;
  2. 18 to 50 years of age, at the enrollment visit;
  3. BMI < 33 kg/m2;
  4. No history of androgen use in the six months prior to the first screening visit;
  5. Agreement to use an effective method of contraception with his female partner (refer to Appendix 11 for acceptable forms of contraception) during the suppression and recovery phases and then only use the experimental method during the efficacy phase of the study;
  6. In the opinion of the investigator, the male subject is willing and able to comply with the protocol;
  7. The subject is legally competent, has been informed of the nature, the scope and the relevance of the study, voluntarily agrees to participation and the study's provisions and has duly signed the informed consent form (ICF);
  8. Sexually active with a female partner (as specified below) with whom he has been in a stable, mutually monogamous relationship for at least 1 year prior to screening and with whom he intends to remain in a relationship for the duration of the study;
  9. Normal reproductive state as demonstrated by:

    • Sperm concentration ≥15 million/mL in two semen samples and with no gross abnormalities of sperm motility and morphology on at least one semen sample assessment;
    • Screening Testosterone within the study site's local lab normal reference range for adult men;
  10. Willingness to accept a low but unknown risk of conceiving a pregnancy for the duration of the trial.

Female participant - Inclusion Criteria

Women who meet all the following criteria will be eligible for enrollment in the trial:

  1. Good general health with no chronic medical conditions that result in periodic exacerbations which require significant medical care or are known to affect fertility;
  2. Aged between 18 and 34 years, inclusive, at the enrollment visit;
  3. Have regular menstrual cycles of 21-35 days in duration, per patient report, when not using hormonal contraception. If hormonal contraception has been used, the following applies:

    1. If recently used intramuscular Depo-Provera must have had last injection at least 3 months prior enrollment;
    2. If using an IUD or an implant, she is planning to have this removed for purposes unrelated to enrollment in the study prior to entering the efficacy phase;
    3. Completion of her last pack of oral contraceptives or completion of effectiveness period for a monthly injection, patch or ring if any has been used prior to entering the efficacy phase;
  4. Have intact uterus and both ovaries (waivers for women who have one ovary may be submitted so that the circumstances related to prior ovarian removal can be assessed);
  5. The subject is legally competent, has been informed of the nature, the scope and the relevance of the study, voluntarily agrees to participation and the study's provisions and has duly signed the informed consent form (ICF);
  6. Consistent use of effective contraception during the preceding cycle prior to enrolling;
  7. No known infertility;
  8. Intends to remain in a monogamous relationship with male study partner (as specified above). (Note: this study will not provide her contraception for intercourse with any other male partners);
  9. Be at risk for pregnancy with participating male partner (heterosexual vaginal intercourse at least once per cycle and not sterilized);
  10. Have a negative pregnancy test at enrollment;
  11. Willingness to accept a low but unknown risk of pregnancy and able to understand the need for follow-up in case of pregnancy;
  12. No medical contraindication to pregnancy;

Exclusion Male participant - Exclusion Criteria

Men who meet any of the following criteria are not eligible for enrollment in the trial:

  1. Men participating in another clinical trial involving an investigational drug within the last 30 days (or within five half-lives of the investigational drug, whichever is longer) prior to the first screening visit.
  2. Men not living in the catchment's area of the study site or within a reasonable distance from the site.
  3. Clinically significant abnormal findings at screening per the Investigator's medical judgment.
  4. Elevated PSA levels ≥ 4 ng/mL.
  5. Abnormal serum chemistry values that may indicate clinically significant liver or kidney dysfunction.
  6. Use of androgens or other anabolic steroids that may suppress gonadotropins within 6 months prior to the first screening visit.
  7. Diastolic blood pressure (DBP) ≥ 85 and Systolic blood pressure (SBP) ≥ 135 mm Hg; (BP will be taken three times at approximately 5 minute intervals and the mean of the 3 measurements will be used to determine eligibility).
  8. History of hypertension, including hypertension controlled with treatment.
  9. Known history of primary testicular disease or disorders of the hypothalamic-pituitary axis.
  10. Known hypersensitivity to progestins or testosterone or any excipient of the investigational product.
  11. History of prostate, testicular or breast carcinoma.
  12. Significant prostatic symptoms (IPSS > 15).
  13. Known history of reproductive dysfunction including vasectomy or infertility.
  14. Known history of significant cardiac, renal, hepatic or prostatic disease.
  15. History of thromboembolic disease.
  16. A serious systemic disease such as diabetes mellitus (including diabetes controlled with treatment), HIV, or morbid obesity.
  17. Current active or ongoing Hepatitis infection.
  18. History of untreated sleep apnea.
  19. Known or suspected current alcohol dependence syndrome, chronic marijuana use, or any illicit drug use that may affect metabolism/transformation of steroid hormones and study treatment compliance.
  20. Any known active or chronic dermatitis or other severe skin disorder.
  21. Any skin condition that might interfere with absorption of gel.
  22. Couples desiring fertility within the study participation period (approximately 104 weeks from screening to end of recovery).
  23. PHQ9 score ≥15 or history of severe depression or other serious mental health disorder, including ongoing use of an anti-depressant.
  24. Men participating in competitive sports where drug screening for prohibited substances (including anabolic steroids) is routine. Exclusion is due to the potential of testing positive for androgens that may occur from their study participation coupled with the unknown efficacy (i.e. duration of positive testing) of a single application.
  25. Use of sex steroids or medications which might interfere with steroid metabolism (i.e. ketoconazole, finasteride, oral corticosteroids, dutasteride and statins).
  26. Use of anticoagulants.
  27. Use of medications that will interfere or interact with Nestorone or Testosterone.
  28. Use of oily cosmetic skin gels/products that would prevent absorption of steroids.
  29. Previous participation in this clinical trial.
  30. Any site staff member with delegated study responsibilities or a family member of a site staff member with delegated study responsibilities.

Female participant - Exclusion Criteria

  1. Desire to become pregnant during the study.
  2. Breastfeeding.
  3. Known or suspected current alcoholism or drug abuse.
  4. Participation in another clinical trial involving an investigational drug within the last 30 days prior to the first screening visit.
  5. Currently pregnant.
  6. Known hypersensitivity to progestins or testosterone.
  7. History associated with impaired fertility (e.g. history of pelvic inflammatory disease, unilateral salpingectomy or endometriosis).
  8. Previous participation in this clinical trial.
  9. Any site staff member with delegated study responsibilities or a family member of a site staff member with delegated study responsibilities.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03452111


Locations
United States, California
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, California, United States, 90509
United States, Kansas
University of Kansas Not yet recruiting
Kansas City, Kansas, United States, 66160
Contact: Katie Glavin    913-588-8721    kglavin@kumc.edu   
Principal Investigator: Ajay Nangia, MBBS, FACS         
United States, Washington
University of Washington Medical Center & Health Sciences
Seattle, Washington, United States, 98195
Chile
Chilean Institute of Reproductive Medicine Not yet recruiting
Santiago, Chile
Contact: Veronica Reyes       vreyes@icmer.org   
Principal Investigator: Gabriela Noe, MS         
Italy
University of Bologna Not yet recruiting
Bologna, Italy
Contact: Giulia Gava       gava.giulia@hotmail.it   
Principal Investigator: Cristina Meriggiola         
Kenya
Kenyatta National Hospital Not yet recruiting
Nairobi, Kenya
Contact: Sheila Eshiwani       seshiwanin@gmail.com   
Principal Investigator: John Kinuthia, MBChB, MPH         
Sweden
Karolinska Institutet Not yet recruiting
Stockholm, Sweden
Contact: Eva Broberg    46(8)517 721 28    eva.k.broberg@karolinska.se   
Principal Investigator: Kristina Gemzell Danielsson, MD         
United Kingdom
University of Edinburgh Not yet recruiting
Edinburgh, United Kingdom
Contact: Anne Saunderson    0131 242 2669    A.Saunderson@ed.ac.uk   
Principal Investigator: Richard Anderson, MD, PhD         
University of Manchester Not yet recruiting
Manchester, United Kingdom
Contact: Kate Barugh    0161 27 66201    Kate.Barugh@cmft.nhs.uk   
Principal Investigator: Cheryl Fitzgerald, MD         
Sponsors and Collaborators
Health Decisions
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Population Council

Responsible Party: Health Decisions
ClinicalTrials.gov Identifier: NCT03452111     History of Changes
Other Study ID Numbers: CCN017
First Posted: March 2, 2018    Key Record Dates
Last Update Posted: July 12, 2018
Last Verified: July 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Health Decisions:
Healthy Men
Couple
Gel
Male Contraception
Nestorone
Testosterone

Additional relevant MeSH terms:
Testosterone
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Methyltestosterone
ST 1435
Androgens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents